Publications
2024
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.
Fleeman, N., Houten, R., Nevitt, S., Mahon, J., Beale, S., Boland, A., . . . Waddell, T. (2024). Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.. Health technology assessment (Winchester, England), 28(49), 1-190. doi:10.3310/trrm4238
2023
Upadacitinib for treating moderately to severely active ulcerative colitis [ID3953]
Greenhalgh, J., Mahon, J., Houten, R., Edwards, K., Donegan, S., Boland, A., . . . Mcentee, J. (2023). Upadacitinib for treating moderately to severely active ulcerative colitis [ID3953]: Upadacitinib for treating moderately to severely active ulcerative colitis[ID3953]. Retrieved from https://www.fundingawards.nihr.ac.uk/award/NIHR135585
Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.. PharmacoEconomics - open, 7(6), 1015. doi:10.1007/s41669-023-00462-7
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - Open. doi:10.1007/s41669-023-00439-6
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bresnahan, R., Houten, R., Greenhalgh, J., Nevitt, S., Mahon, J., Beale, S., . . . Chaplin, M. (2023). Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. PharmacoEconomics - open. doi:10.1007/s41669-023-00408-z
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]
Greenhalgh, J., Mahon, J., Bryning, S., Chaplin, M., Beale, S., Boland, A., . . . Basu, B. (2023). Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]. Retrieved from https://www.nice.org.uk/guidance/gid-ta10920/documents/committee-papers
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Houten, R., Fleeman, N., Mahon, J., Chaplin, M., Edwards, K., Beale, S., . . . Palmieri, C. (2023). Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN. doi:10.1007/s41669-023-00405-2
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.
Bresnahan, R., Duarte, R., Mahon, J., Beale, S., Chaplin, M., Bhattacharyya, D., . . . Boland, A. (2023). Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.. Health technology assessment (Winchester, England), 27(10), 1-115. doi:10.3310/kgju3398
2022
Systematic review of the effect of policies to restrict the marketing of foods and non-alcoholic beverages to which children are exposed
Boyland, E., McGale, L., Maden, M., Hounsome, J., Boland, A., & Jones, A. (2022). Systematic review of the effect of policies to restrict the marketing of foods and non-alcoholic beverages to which children are exposed. OBESITY REVIEWS, 23(8). doi:10.1111/obr.13447
Association of Food and Nonalcoholic Beverage Marketing With Children and Adolescents' Eating Behaviors and Health A Systematic Review and Meta-analysis
Boyland, E., McGale, L., Maden, M., Hounsome, J., Boland, A., Angus, K., & Jones, A. (2022). Association of Food and Nonalcoholic Beverage Marketing With Children and Adolescents' Eating Behaviors and Health A Systematic Review and Meta-analysis. JAMA PEDIATRICS, 176(7). doi:10.1001/jamapediatrics.2022.1037
2021
Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]
Greenhalgh, J., Mahon, J., Nevitt, S., Bresnahan, R., Boland, A., Beale, S., . . . Boon, C. (2021). Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]: Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
Greenhalgh, J., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Chaplin, M., & Green, J. A. (2021). First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (3). doi:10.1002/14651858.CD010383.pub3
A systematic review of health state utility values for thyroid cancer
Houten, R., Fleeman, N., Kotas, E., Boland, A., Lambe, T., & Duarte, R. (2021). A systematic review of health state utility values for thyroid cancer. QUALITY OF LIFE RESEARCH, 30(3), 675-702. doi:10.1007/s11136-020-02676-2
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Houten, R., Greenhalgh, J., Mahon, J., Nevitt, S., Beale, S., Boland, A., . . . McEntee, J. (2021). Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 5(1), 13-22. doi:10.1007/s41669-020-00206-x
Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users
O'Flaherty, M., Lloyd-Williams, F., Capewell, S., Boland, A., Maden, M., Collins, B., . . . Kypridemos, C. (2021). Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users. HEALTH TECHNOLOGY ASSESSMENT, 25(35), 1-+. doi:10.3310/hta25350
2020
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]
Bresnahan, R., Mahon, J., Nevitt, S., Beale, S., Boland, A., Greenhalgh, J., . . . Campbell, L. (2020). Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]: Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/rebecca-bresnahan/
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Stainthorpe, A., Fleeman, N., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Syndikus, I. (2020). Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 4(4), 563-574. doi:10.1007/s41669-020-00203-0
Sapropterin dihydrochloride for treating phenylketonuria [ID1475]
Greenhalgh, J., James, M., Nevitt, S., Bresnahan, R., Beale, S., Boland, A., . . . Schwan, B. (2020). Sapropterin dihydrochloride for treating phenylketonuria [ID1475]: Sapropterin dihydrochloride for treating phenylketonuria [ID1475]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]
Greenhalgh, J., Lambe, T., Mahon, J., Nevitt, S., Edwards, K., Bresnahan, R., . . . Green, J. (2020). Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]: Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation
Hounsome, J., Pilkington, G., Mahon, J., Boland, A., Beale, S., Kotas, E., . . . Dickson, R. (2020). Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation. Health Technology Assessment, 24(30). doi:10.3310/hta24300
Midostaurin for treating advanced systemic mastocytosis [ID1573]
Greenhalgh, J., Lambe, T., Nevitt, S., Mahon, J., Boland, A., Beale, S., . . . Moonim, M. (2020). Midostaurin for treating advanced systemic mastocytosis [ID1573]: Midostaurin for treating advanced systemic mastocytosis [ID1573]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Engaging with stakeholders to inform the development of a decision-support tool for the NHS health check programme: qualitative study
Hyseni, L., Guzman-Castillo, M., Kypridemos, C., Collins, B., Schwaller, E., Capewell, S., . . . Lloyd-Williams, F. (2020). Engaging with stakeholders to inform the development of a decision-support tool for the NHS health check programme: qualitative study. BMC HEALTH SERVICES RESEARCH, 20(1). doi:10.1186/s12913-020-05268-5
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
Greenhalgh, J., Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., . . . Goodson, N. (2020). Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: Ixekizumab for treating axial spondyloarthritis after NSAIDs[ID1532]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation
Duarte, R., Stainthorpe, A., Greenhalgh, J., Richardson, M., Nevitt, S., Mahon, J., . . . Takwoingi, Y. (2020). Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24(3), 1-+. doi:10.3310/hta24030
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Fleeman, N., Houten, R., Bagust, A., Richardson, M., Beale, S., Boland, A., . . . Shenoy, A. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24(2), 1-+. doi:10.3310/hta24020
2019
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., Dundar, Y., . . . Shenoy, A. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC CANCER, 19(1). doi:10.1186/s12885-019-6369-7
Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Fleeman, N., Mahon, J., Nevitt, S., Duarte, R., Boland, A., Kotas, E., . . . Ahmad, S. (2019). Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 3(4), 453-461. doi:10.1007/s41669-019-0138-z
Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluation
Duarte, R., Stainthorpe, A., Mahon, J., Greenhalgh, J., Richardson, M., Nevitt, S., . . . Takwoingi, Y. (2019). Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluation. PLOS ONE, 14(12). doi:10.1371/journal.pone.0226671
Umbrella review of strategies to improve uptake of screening programmes
Hyseni, L., Maden, M., Boland, A., Kypridemos, C., Collins, B., & O'Flaherty, M. (2019). Umbrella review of strategies to improve uptake of screening programmes. In EUROPEAN JOURNAL OF PUBLIC HEALTH Vol. 29. Retrieved from https://www.webofscience.com/
EVALUATING STAKEHOLDER INVOLVEMENT IN BUILDING A DECISION SUPPORT TOOL FOR NHS HEALTH CHECKS: CO-PRODUCING THE WORKHORSE STUDY
Lloyd-Williams, F., Hyseni, L., Guzman-Castillo, M., Kypridemos, C., Collins, B., Capewell, S., . . . O'Flaherty, M. (2019). EVALUATING STAKEHOLDER INVOLVEMENT IN BUILDING A DECISION SUPPORT TOOL FOR NHS HEALTH CHECKS: CO-PRODUCING THE WORKHORSE STUDY. In JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH Vol. 73 (pp. A87). doi:10.1136/jech-2019-SSMabstracts.185
Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Fleeman, N., Bagust, A., Duarte, R., Richardson, M., Nevitt, S., Boland, A., . . . Thorp, N. (2019). Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 3(3), 293-302. doi:10.1007/s41669-018-0114-z
Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck
Greenhalgh, J., Mahon, J., Chaplin, M., Nevitt, S., Boland, A., Beale, S., . . . Shaw, R. (2019). Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck: Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck (17/56/06). NICE website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10181/documents/committee-papers
Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer
Greenhalgh, J., Mahon, J., Chaplin, M., Beale, S., Boland, A., Lambe, T., . . . Palmieri, C. (2019). Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer: Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer (128748). NICE website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10433/documents/committee-papers
Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Lambe, T., Duarte, R., Mahon, J., Nevitt, S., Greenhalgh, J., Boland, A., . . . Pomeroy, I. (2019). Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 37(3), 345-357. doi:10.1007/s40273-018-0718-2
The effect of orthodontic treatment on traumatised teeth : a systematic review and vignette study
Al Hourani, A. (2019). The effect of orthodontic treatment on traumatised teeth : a systematic review and vignette study.
2018
Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer
Fleeman, N., Mahon, J., Chaplin, M., Boland, A., Beale, S., De Sousa Rego Vieira Duarte, R., . . . Green, J. (2018). Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer: Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non- small-cell lung cancer (17/141/08). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta621/documents/committee-papers
Engaging with stakeholders to inform the development of a computer model for the NHS Health Check programme: a qualitative study
Hyseni, L., Guzman-Castillo, M., Kypridemos, C., Collins, B., Schwaller, E., Capewell, S., . . . Lloyd-Williams, F. (2018). Engaging with stakeholders to inform the development of a computer model for the NHS Health Check programme: a qualitative study. In LANCET Vol. 392 (pp. 45). Retrieved from http://gateway.webofknowledge.com/
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12)
Fleeman, N., Stainthorpe, A., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Isabel, S. (2018). Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12): Brentuximab vedotin for treating relapsed or refractory CD30- positive cutaneous T-cell lymphoma (17/56/12). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta577/documents/committee-papers
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Stainthorpe, A., Greenhalgh, J., Bagust, A., Richardson, M., Boland, A., Beale, S., . . . Palmer, D. (2018). Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1153-1163. doi:10.1007/s40273-018-0646-1
ENGAGING WITH STAKEHOLDERS TO INFORM THE DEVELOPMENT OF A COMPUTER MODEL FOR THE NHS HEALTH CHECK PROGRAMME: WORKHORSE PROJECT
Hyseni, L., Guzman-Castillo, M., Kypridemos, C., Collins, B., Schwaller, E., Capewell, C., . . . Lloyd-Williams, F. (2018). ENGAGING WITH STAKEHOLDERS TO INFORM THE DEVELOPMENT OF A COMPUTER MODEL FOR THE NHS HEALTH CHECK PROGRAMME: WORKHORSE PROJECT. In JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH Vol. 72 (pp. A74-A75). doi:10.1136/jech-2018-SSMabstracts.157
EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
Dickson, R., Boland, A., Duarte, R., Kotas, E., Woolacott, N., Hodgson, R., . . . Brazzelli, M. (2018). EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 16(4), 429-432. doi:10.1007/s40258-018-0393-7
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Greenhalgh, J., Mahon, J., Nevitt, S., Beale, S., Boland, A., Lambe, T., . . . Marshall, E. (2018). Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (17/109/17). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta553/documents/committee-papers
A systematic review of the diagnostic accuracy of automated tests for cognitive impairment
Aslam, R. W., Bates, V., Dundar, Y., Hounsome, J., Richardson, M., Krishan, A., . . . Sikdar, S. (2018). A systematic review of the diagnostic accuracy of automated tests for cognitive impairment. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 33(4), 561-575. doi:10.1002/gps.4852
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Fleeman, N., Abdulla, A., Bagust, A., Beale, S., Richardson, M., Stainthorpe, A., . . . Palmer, D. (2018). Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 36(3), 289-299. doi:10.1007/s40273-017-0592-3
Cost Savings and Improved Patient Outcomes from Best Management of Epilepsy
Marson, T., Boland, A., Mahon, J., Little, A., Dickson, R., Boon, P., . . . Kalviainen, R. (2018). Cost Savings and Improved Patient Outcomes from Best Management of Epilepsy. In EPILEPSIA Vol. 59 (pp. S28-S29). Retrieved from https://www.webofscience.com/
2017
Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen
Fleeman, N., Bagust, A., Duarte, R., Chaplin, M., Nevitt, S., Boland, A., . . . Thorp, N. (n.d.). Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen (ID1072). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta515/documents/committee-papers
Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Fleeman, N., Bagust, A., Boland, A., Beale, S., Richardson, M., Krishan, A., . . . Payne, M. (2017). Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 35(10), 1035-1046. doi:10.1007/s40273-017-0504-6
WHAT DO THE SINGLE TECHNOLOGY APPRAISALS OF THE PAST TELL US ABOUT FAST-TRACKING THE MOST COST-EFFECTIVE NEW TECHNOLOGIES IN THE FUTURE?
Boland, A., Houten, R., Carroll, C., Kaltenthauer, E., & Dickson, R. (2017). WHAT DO THE SINGLE TECHNOLOGY APPRAISALS OF THE PAST TELL US ABOUT FAST-TRACKING THE MOST COST-EFFECTIVE NEW TECHNOLOGIES IN THE FUTURE?. In VALUE IN HEALTH Vol. 20 (pp. A410). doi:10.1016/j.jval.2017.08.075
What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll, C., Houten, R., Boland, A., Kaltenthaler, E., & Dickson, R. C. (2017). What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?. Value in Health, 21(3), 341-350. doi:10.1016/j.jval.2017.09.006
Cladribine for the treatment of relapsing-remitting multiple sclerosis
Duarte, R., Mahon, J., Nevitt, S., Greenhalgh, J., Boland, A., Beale, S., . . . Mcentee, J. (n.d.). Cladribine for the treatment of relapsing-remitting multiple sclerosis (ID64). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta493/documents/committee-papers
Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer
Greenhalgh, J. (n.d.). Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (ID1059). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta535/documents/committee-papers
Nab-paclitaxel with gemcitabine for 1st line metastatic pancreatic adenocarcinoma
Greenhalgh, J. (n.d.). Nab-paclitaxel with gemcitabine for 1st line metastatic pancreatic adenocarcinoma (ID1058). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta476/documents/committee-papers
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Greenhalgh, J., Bagust, A., Stainthorpe, A., Chaplin, M., Boland, A., De Sousa Rego Vieira Duarte, R., . . . Palmer, D. (2017). Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (14/90/01). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta476/documents/committee-papers
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy
Greenhalgh, J. (n.d.). Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy (ID970). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta520/documents/committee-papers
Comprehensive geriatric assessment for older people with cancer
Pilkington, G., Boland, A., & Dickson, R. (2017). Comprehensive geriatric assessment for older people with cancer. Cancer Nursing Practice, 16(1), 25-30. doi:10.7748/cnp.2017.e1321
Crizotinib for treating ROS1positive advanced non-small cell lung cancer
Greenhalgh, J., Stainthorpe, S., Richardson, M., Duarte, R., Boland, A., Kotas, E., . . . Green, J. (2017). Crizotinib for treating ROS1positive advanced non-small cell lung cancer (D1098).
2016
Palbociclib for treating metastatic, hormone receptor-positive, HER2-negative breast cancer
Greenhalgh, J. (n.d.). Palbociclib for treating metastatic, hormone receptor-positive, HER2-negative breast cancer (ID915). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta495/documents/committee-papers-2
Automated tests for diagnosing and monitoring cognitive impairment: a diagnostic accuracy review
Aslam, R. W., Bates, V., Dundar, Y., Hounsome, J., Richardson, M., Krishan, A., . . . Robinson, L. (2016). Automated tests for diagnosing and monitoring cognitive impairment: a diagnostic accuracy review. Health Technology Assessment, 20(77). doi:10.3310/hta20770
Ex vivo expanded autologous human corneal epithelial cells for treating moderate to severe limbal stem cell deficiency due to ocular burns
Greenhalgh, J. (n.d.). Ex vivo expanded autologous human corneal epithelial cells for treating moderate to severe limbal stem cell deficiency due to ocular burns (ID899). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta467/documents/committee-papers-3
Automated tests for diagnosing and monitoring cognitive impairment: a diagnostic accuracy review
Aslam, R. W., Bates, V., Dundar, Y., Hounsome, J., Richardson, M., Krishan, A., . . . Robinson, L. (2016). Automated tests for diagnosing and monitoring cognitive impairment: a diagnostic accuracy review. Health technology assessment (Winchester, England), 20(77), 1-74.
Eribulin for locally advanced or metastatic breast cancer
Greenhalgh, J. (n.d.). Eribulin for locally advanced or metastatic breast cancer (ID964). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10030/documents/committee-papers
Nanoliposomal irinotecan for treating pancreatic cancer after prior treatment with gemcitabine
Greenhalgh, J. (n.d.). Nanoliposomal irinotecan for treating pancreatic cancer after prior treatment with gemcitabine (ID778). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta440/documents/committee-papers-2
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
Greenhalgh, J., Dwan, K., Boland, A., Bates, V., Vecchio, F., Dundar, Y., . . . Green, J. A. (2016). First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD010383.pub2
Nivolumab for treating metastatic, non-squamous, non-small-cell lung cancer after chemotherapy
Greenhalgh, J. (n.d.). Nivolumab for treating metastatic, non-squamous, non-small-cell lung cancer after chemotherapy (ID900). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta484/documents/committee-papers
Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma
Greenhalgh, J., Mahon, J., Beale, S., Boland, A., Krishan, A., Chaplin, M., . . . Steven, N. (2016). Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma: Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma (12/50/01). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta396/history
Talimogene laherparepvec for treating metastatic melanoma
Fleeman, N., Bagust, A., Boland, A., Beale, S., Chaplin, M., Krishan, A., . . . Payne, M. (2016). Talimogene laherparepvec for treating metastatic melanoma: Talimogene laherparepvec for treating metastatic melanoma (14/206/04). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-tag509/documents/committee-papers-2
Introduction
Powell, C. V. E., Kolamunnage-Dona, R., Lowe, J., Boland, A., Petrou, S., Doull, I., . . . Williamson, P. R. (2013). Introduction. In Unknown Book (Vol. 17, pp. 1-+). Retrieved from https://www.webofscience.com/
Osimertinib for treating locally advanced or metastatic EGFR and T790M mutation-positive non-small cell lung cancer
Greenhalgh, J., Aslam, R. W., Mahon, J., Krishan, A., Boland, A., Beale, S., . . . Green, J. (2016). Osimertinib for treating locally advanced or metastatic EGFR and T790M mutation-positive non-small cell lung cancer: Osimertinib for treating locally advanced or metastatic EGFR and T790M mutation-positive non-small cell lung cancer (ID 874).
Pembrolizumab for untreated PD-L1 positive metastatic non-small cell lung cancer
Greenhalgh, J., Mahon, J., Boland, A., Beale, S., Krishan, A., Abdulla, A., . . . Green, J. (2016). Pembrolizumab for untreated PD-L1 positive metastatic non-small cell lung cancer: Pembrolizumab for untreated PD-L1 positive metastatic non-small cell lung cancer (ID990).
2015
The clinical effectiveness and cost-effectiveness of the PROGENSA (R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation
Nicholson, A., Mahon, J., Boland, A., Beale, S., Dwan, K., Fleeman, N., . . . Dundar, Y. (2015). The clinical effectiveness and cost-effectiveness of the PROGENSA (R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technology Assessment, 19(87), 1-+. doi:10.3310/hta19870
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2015). Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. PHARMACOECONOMICS, 33(9), 893-904. doi:10.1007/s40273-015-0276-9
Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab
Fleeman, N., Bagust, A., Chaplin, M., Krishan, A., Boland, A., Beale, S., . . . Payne, M. (2015). Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab: Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab (14/177/07). NICE Website. Retrieved from https://www.nice.org.uk/
Pembrolizumab for treating advanced melanoma in people previously untreated with ipilimumab
Greenhalgh, J., Mahon, J., Chaplin, M., Krishan, A., Aslam, R., Beale, S., . . . Payne, M. (2015). Pembrolizumab for treating advanced melanoma in people previously untreated with ipilimumab: Pembrolizumab for treating advanced melanoma in people previously untreated with ipilimumab (14/177/06). NICE website. Retrieved from https://www.nice.org.uk/guidance/TA366/documents/committee-papers
Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown, T., Pilkington, G., Bagust, A., Boland, A., Oyee, J., Tudur Smith, C., . . . Dickson, R. (2015). Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 17(31), 281-282. doi:10.3310/hta17310-c201505
Ciclosporin for treating dry eye disease
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dwan, K., Kotas, E., . . . Ahmad, S. (2015). Ciclosporin for treating dry eye disease: Ciclosporin for treating dry eye disease (13/166/01). NICE Website. Retrieved from https://www.nice.org.uk/
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer
Pilkington, G., Boland, A., Brown, T., Oyee, J., Bagust, A., & Dickson, R. (2015). A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. THORAX, 70, 359-367. doi:10.1136/thoraxjnl-2014-205914
Edoxaban tosylate for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Greenhalgh, J., Longworth, L., Crossan, C., Singh, J., Bagust, A., Boland, A., . . . Hall, M. (2015). Edoxaban tosylate for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: Edoxaban tosylate for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (14/14/01). NICE website. Retrieved from https://www.nice.org.uk/
Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal
Greenhalgh, J., Bagust, A., Boland, A., Oyee, J., Trevor, N., Beale, S., . . . O'Reilly, S. (2015). Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. PharmacoEconomics, 33(2), 137-148. doi:10.1007/s40273-014-0214-2
A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children
Beale, S., Sanderson, D., Sanniti, A., Dundar, Y., & Boland, A. (2015). A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children. HEALTH TECHNOLOGY ASSESSMENT, 19(46), I-90. doi:10.3310/hta19460
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation
Greenhalgh, J., Bagust, A., Boland, A., Dwan, K., Beale, S., Hockenhull, J., . . . Marshall, E. (2015). Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 19(47), I-133. doi:10.3310/hta19470
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis
Greenhalgh, J., Bagust, A., Boland, A., Dwan, K., Beale, S., Fleeman, N., . . . Fisher, M. (2015). Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 19(29), 1-+. doi:10.3310/hta19290
Systematic review to examine the clinical effectiveness and tolerability of chemotherapy for older people with non - Hodgkin’s lymphoma
Pilkington, G., Greenhalgh, J., Aslam, R. W., Boland, A., Joanne, F., Dickson, R. C., . . . Bates, V. (n.d.). Systematic review to examine the clinical effectiveness and tolerability of chemotherapy for older people with non - Hodgkin’s lymphoma: Systematic review to examine the clinical effectiveness and tolerability of chemotherapy for older people with non-Hodgkin’s lymphoma.
Systematic review to examine the clinical effectiveness and tolerability of systemic anti-cancer therapy for older people with chronic myeloid leukaemia
Bates, V., Pilkington, G. M., Dickson, R. C., Boland, A., Dundar, Y., & Clark, R. (n.d.). Systematic review to examine the clinical effectiveness and tolerability of systemic anti-cancer therapy for older people with chronic myeloid leukaemia.
Systematic review to examine the clinical effectiveness and tolerability of chemotherapy treatment for older people with colorectal cancer
Pilkington, G. M., Boland, A., Dickson, R. C., Bates, V., Dundar, Y., & Saunders, M. (n.d.). Systematic review to examine the clinical effectiveness and tolerability of chemotherapy treatment for older people with colorectal cancer.
2014
Nintedanib for previously treated locally advanced or metastatic non small cell lung cancer
Fleeman, N., Bagust, A., Boland, A., Dwan, K., Chaplin, M., Beale, S., . . . Greystoke, A. (2014). Nintedanib for previously treated locally advanced or metastatic non small cell lung cancer: Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer (13/106/01). NICE Website. Retrieved from https://www.nice.org.uk/
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Greenhalgh, J., Bagust, A., Beale, S., Boland, A., Chaplin, M., Dwan, K., . . . Hall, M. (2014). Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (14/15/01). NICE website. Retrieved from https://www.nice.org.uk/
ECONOMIC EVALUATION OF NEBULIZED MAGNESIUM SULPHATE IN ACUTE SEVERE ASTHMA IN CHILDREN
Petrou, S., Boland, A., Khan, K., Powell, C., Kolamunnage-Dona, R., Lowe, J., . . . Williamson, P. (2014). ECONOMIC EVALUATION OF NEBULIZED MAGNESIUM SULPHATE IN ACUTE SEVERE ASTHMA IN CHILDREN. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 30(4), 354-360. doi:10.1017/S0266462314000440
Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2014). Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma: Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma (12/54). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta321/history
Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges
Miceli, R., Tomasello, G., Bregni, G., Di Bartolomeo, M., & Pietrantonio, F. (2014). Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges. WORLD JOURNAL OF GASTROENTEROLOGY, 20(16), 4516-4525. doi:10.3748/wjg.v20.i16.4516
Allopurinol for the treatment of chronic kidney disease: a systematic review
Fleeman, N., Pilkington, G., Dundar, Y., Dwan, K., Boland, A., Dickson, R., . . . Pyatt, J. (2014). Allopurinol for the treatment of chronic kidney disease: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 18(40), 1-+. doi:10.3310/hta18400
Doing a Systematic Review: A Student's Guide
Boland, A., Cherry, G., & Dickson, R. (Eds.) (2014). Doing a Systematic Review: A Student's Guide (1st ed.). London: SAGE Publications.
Prospective multicentre randomised, double-blind, equivalence study comparing clonidine and midazolam as intravenous sedative agents in critically ill children: the SLEEPS (Safety profiLe, Efficacy and Equivalence in Paediatric intensive care Sedation) study
Wolf, A., McKay, A., Spowart, C., Granville, H., Boland, A., Petrou, S., . . . Gamble, C. (2014). Prospective multicentre randomised, double-blind, equivalence study comparing clonidine and midazolam as intravenous sedative agents in critically ill children: the SLEEPS (Safety profiLe, Efficacy and Equivalence in Paediatric intensive care Sedation) study. Health Technology Assessment, 18(71), 1-212. doi:10.3310/hta18710
2013
Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal
Beale, S., Dickson, R., Bagust, A., Blundell, M., Dundar, Y., Boland, A., . . . Proudlove, C. (2013). Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal. PHARMACOECONOMICS, 31(12), 1121-1129. doi:10.1007/s40273-013-0094-x
Planning and Managing My Review
Pilkington, G. (2013). Planning and Managing My Review. In A. Boland, M. cHERRY, & R. dICKSON (Eds.), Doing a Systematic Review A Student's Guide. SAGE.
Are health technology assessments of pharmacogenetic tests feasible? A case study of <i>CYP2D6</i> testing in the treatment of breast cancer with tamoxifen
Fleeman, N., Payne, K., Newman, W. G., Howell, S. J., Boland, A., Oyee, J., . . . Dickson, R. (2013). Are health technology assessments of pharmacogenetic tests feasible? A case study of <i>CYP2D6</i> testing in the treatment of breast cancer with tamoxifen. PERSONALIZED MEDICINE, 10(6), 601-611. doi:10.2217/pme.13.60
Description of health problem
Brown, T., Pilkington, G., Bagust, A., Boland, A., Oyee, J., Smith, C. T., . . . Dickson, R. (2013). Description of health problem. HEALTH TECHNOLOGY ASSESSMENT, 17(31), 1-+. doi:10.3310/hta17310
Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial
Powell, C., Kolamunnage-Dona, R., Lowe, J., Boland, A., Petrou, S., Doull, I., . . . Williamson, P. (2013). Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. LANCET RESPIRATORY MEDICINE, 1(4), 301-308. doi:10.1016/S2213-2600(13)70037-7
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
Green, J. A., Bates, V., Greenhalgh, J., Boland, A., Jain, P., Dickson, R. C., . . . Vecchio, F. (n.d.). First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. doi:10.1002/14651858.cd010383
Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review
Brown, T., Pilkington, G., Boland, A., Oyee, J., Smith, C. T., Dundar, Y., . . . Dickson, R. (2013). Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 17(6), 1-+. doi:10.3310/hta17060
Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review
Brown, T., Pilkington, G., Boland, A., Oyee, J., Tudur Smith, C., Dundar, Y., . . . Dickson, R. (n.d.). Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. Health Technology Assessment, 17(6), 1-99. doi:10.3310/hta17060
Erlotinib in monoterapia nel trattamento di mantenimento del carcinoma polmonare non a piccole cellule dopo chemioterapia a base di platino
Dickson, R., Bagust, A., Boland, A., Blundell, M., Davis, H., Dundar, Y., . . . Ramani, V. S. (2013). Erlotinib in monoterapia nel trattamento di mantenimento del carcinoma polmonare non a piccole cellule dopo chemioterapia a base di platino. PharmacoEconomics Italian Research Articles, 15(1), 35-44. doi:10.1007/s40276-013-0004-4
MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children.
Powell, C. V. E., Kolamunnage-Dona, R., Lowe, J., Boland, A., Petrou, S., Doull, I., . . . MAGNETIC study group. (2013). MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children.. Health technology assessment (Winchester, England), 17(45), v-216. doi:10.3310/hta17450
Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin's Lymphoma A NICE Single Technology Appraisal
Greenhalgh, J., Bagust, A., Boland, A., Blundell, M., Oyee, J., Beale, S., . . . Chu, P. (2013). Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin's Lymphoma A NICE Single Technology Appraisal. PHARMACOECONOMICS, 31(5), 403-413. doi:10.1007/s40273-013-0043-8
2012
A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.
Hockenhull, J., Elremeli, M., Cherry, M. G., Mahon, J., Lai, M., Darroch, J., . . . Boyle, R. (2012). A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.. Health technology assessment (Winchester, England), 16(12).
The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation
Cherry, M. G., Greenhalgh, J., Osipenko, L., Venkatachalam, M., Boland, A., Dundar, Y., . . . Rees, D. C. (2012). The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 16(43), 1-+. Retrieved from https://www.webofscience.com/
A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process.
Kaltenthaler, E. C., Dickson, R., Boland, A., Carroll, C., Fitzgerald, P., Papaioannou, D., & Akehurst, R. (2012). A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process.. BMJ open, 2, e000562. doi:10.1136/bmjopen-2011-000562
A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy
Hockenhull, J., Elremeli, M., Cherry, M. G., Mahon, J., Lai, M., Darroch, J., . . . Boyle, R. (2012). A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy. HEALTH TECHNOLOGY ASSESSMENT, 16(12), 1-+. doi:10.3310/hta16120
2011
The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
Kaltenthaler, E., Papaioannou, D., Boland, A., & Dickson, R. (2011). The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 14(8), 1158-1165. doi:10.1016/j.jval.2011.06.007
Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy A NICE Single Technology Appraisal
Dickson, R., Bagust, A., Boland, A., Blundell, M., Davis, H., Dundar, Y., . . . Ramani, V. S. (2011). Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy A NICE Single Technology Appraisal. PHARMACOECONOMICS, 29(12), 1051-1062. doi:10.2165/11591600-000000000-00000
A thematic analysis of the strengths and weaknesses of manufacturers' submissions to the NICE Single Technology Assessment (STA) process.
Carroll, C., Kaltenthaler, E., FitzGerald, P., Boland, A., & Dickson, R. (2011). A thematic analysis of the strengths and weaknesses of manufacturers' submissions to the NICE Single Technology Assessment (STA) process.. Health policy (Amsterdam, Netherlands), 102(2-3), 136-144. doi:10.1016/j.healthpol.2011.06.002
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Oyee, J., Blundell, M., . . . Fisher, M. (2011). Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 15(31), 1-+. doi:10.3310/hta15310
The clinical effectiveness and cost-effectiveness of genotyping for <i>CYP2D6</i> for the management of women with breast cancer treated with tamoxifen: a systematic review
Fleeman, N., Martin Saborido, C., Payne, K., Boland, A., Dickson, R., Dundar, Y., . . . Walley, T. (2011). The clinical effectiveness and cost-effectiveness of genotyping for <i>CYP2D6</i> for the management of women with breast cancer treated with tamoxifen: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 15(33), XIII-+. doi:10.3310/hta15330
Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
Kaltenthaler, E., Boland, A., Carroll, C., Dickson, R., Fitzgerald, P., & Papaioannou, D. (2011). Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.. Health technology assessment (Winchester, England), 15(22), 1-iv. doi:10.3310/hta15220
Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE
Bagust, A., Greenhalgh, J., Boland, A., Fleeman, N., McLeod, C., Dickson, R., . . . Shaw, R. (2011). Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE. PharmacoEconomics Italian Research Articles, 13(2), 101-110. doi:10.1007/bf03320687
Do cardiovascular patients with multivascular disease constitute an important clinical subgroup? Data from the CAPRIE trial
Greenhalgh, J., Boland, A., Bagust, A., Dickson, R., & Fisher, M. (2011). Do cardiovascular patients with multivascular disease constitute an important clinical subgroup? Data from the CAPRIE trial. European Heart Journal, 32, 231.
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer (NSCLC)
Dickson, R., Bagust, A., Boland, A., Blundell, M., Brown, T., Davis, H., . . . Ramani, V. (2011). Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer (NSCLC). Health Technology Assessment, in pre.
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
Fleeman, N., Bagust, A., Boland, A., Dickson, R., Dundar, Y., Moonan, M., . . . Thorp, N. (2011). Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 15(42), 1-+. doi:10.3310/hta15420
Mapping of the NICE Single Technology Appraisal (STA) Process
Kaltenthaler, E., Papaioannou, D., Boland, A., & Dickson, R. (2011). Mapping of the NICE Single Technology Appraisal (STA) Process. Value in Health, 18(8), 1158-1165.
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: A Single Technology Appraisal
Greenhalgh, J., Bagust, A., Boland, A., Blundell, M., Oyee, J., Dundar, Y., . . . Chu, P. (2011). Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: A Single Technology Appraisal.
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: A Single Technology Appraisal
Greenhalgh, J., Bagust, A., Boland, A., Blundell, M., Oyee, J., Dundar, Y., . . . Chu, P. (2011). Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: A Single Technology Appraisal.
Ticagrelor for the treatment of acute coronary syndromes: A Single Technology Appraisal
Greenhalgh, J., Bagust, A., Boland, A., Blundell, M., Lai, M., Dundar, Y., . . . Fisher, M. (2011). Ticagrelor for the treatment of acute coronary syndromes: A Single Technology Appraisal.
2010
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
Brown, T., Boland, A., Bagust, A., Oyee, J., Hockenhull, J., Dundar, Y., . . . Proudlove, C. (2010). Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 71-79. doi:10.3310/hta14suppl2/10
Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal
Bagust, A., Greenhalgh, J., Boland, A., Fleeman, N., McLeod, C., Dickson, R., . . . Shaw, R. (2010). Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal. PHARMACOECONOMICS, 28(6), 439-448. doi:10.2165/11532220-000000000-00000
Best supportive care in lung cancer trials is inadequately described: a systematic review.
Jack, B., Boland, A., Dickson, R., Stevenson, J., & McLeod, C. (2010). Best supportive care in lung cancer trials is inadequately described: a systematic review.. European journal of cancer care, 19(3), 293-301. doi:10.1111/j.1365-2354.2008.01064.x
Abatacept for the treatment of rheumatoid arthritis
Hockenhull, J., Boland, A., Bagust, A., Dundar, Y., Fleeman, N., Kennedy, T., . . . Dickson, R. (2010). Abatacept for the treatment of rheumatoid arthritis. Health Technology Assessment. Retrieved from http://www.hta.ac.uk/project/1648.asp
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown, T., Boland, A., Bagust, A., Oyee, J., Hockenhull, J., Dundar, Y., . . . Proudlove, C. (2010). Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.. Health technology assessment (Winchester, England), 14(Suppl. 2), 71-79. doi:10.3310/hta14suppl2/10
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 47-53. doi:10.3310/hta14suppl1/07
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 33-39. doi:10.3310/hta14suppl2/05
Pemetrexed for the treatment of relapsed non-small cell lung cancer
Hockenhull, J., Boland, A., Bagust, A., Dundar, Y., Davis, H., Dickson, R., . . . Proudlove, N. (2010). Pemetrexed for the treatment of relapsed non-small cell lung cancer. Health Technology Assessment. Retrieved from http://www.hta.ac.uk/erg/reports/1641.pdf
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (2010). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. HEALTH TECHNOLOGY ASSESSMENT, 14, 31-38. doi:10.3310/hta14suppl1/05
Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido, C. M., Hockenhull, J., Bagust, A., Boland, A., Dickson, R., & Todd, D. (2010). Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.. Health technology assessment (Winchester, England), 14(31), iii-75. doi:10.3310/hta14310
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation
Fleeman, N., McLeod, C., Bagust, A., Beale, S., Boland, A., Dundar, Y., . . . Dickson, R. (2010). The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 14(3), 1-+. doi:10.3310/hta14030
2009
Erlotinib for the treatment of relapsed non-small cell lung cancer
McLeod, C., Bagust, A., Boland, A., Hockenhull, J., Dundar, Y., Proudlove, C., . . . Dickson, R. (2009). Erlotinib for the treatment of relapsed non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 13, 41-47. doi:10.3310/hta13suppl1/07
Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
Dundar, Y., Bagust, A., Hounsome, J., McLeod, C., Boland, A., Davis, H., . . . Dickson, R. (2009). Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma. HEALTH TECHNOLOGY ASSESSMENT, 13, 23-28. doi:10.3310/hta13suppl1/04
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
Greenhalgh, J., Bagust, A., Boland, A., Fleeman, N., McLeod, C., Dundar, Y., . . . Shaw, R. (2009). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. HEALTH TECHNOLOGY ASSESSMENT, 13, 49-54. doi:10.3310/hta13suppl3/08
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation
McLeod, C., Fleeman, N., Kirkham, J., Bagust, A., Boland, A., Chu, P., . . . Walley, T. (2009). Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 13(1), 1-+. doi:10.3310/hta13010
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
Boland, A., Bagust, A., Hockenhull, J., Davis, H., Chu, P., & Dickson, R. (2009). Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. HEALTH TECHNOLOGY ASSESSMENT, 13, 41-48. doi:10.3310/hta13suppl2/06
Rituximab for the treatment of rheumatoid arthritis
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., . . . Dickson, R. (2009). Rituximab for the treatment of rheumatoid arthritis. HEALTH TECHNOLOGY ASSESSMENT, 13, 23-29. doi:10.3310/hta13suppl2/04
The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: A systematic review
Hockenhull, J. C., Dwan, K. M., Smith, G. W., Gamble, C. L., Boland, A., Walley, T. J., & Dickson, R. C. (2009). The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: A systematic review. CRITICAL CARE MEDICINE, 37(2), 702-712. doi:10.1097/CCM.0b013e3181958915
2008
The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation.
Hockenhull, J. C., Dwan, K., Boland, A., Smith, G., Bagust, A., Dündar, Y., . . . Dickson, R. (2008). The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 12(12), iii-154. doi:10.3310/hta12120
The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation: Abstract
Hockenhull, J. C., Dwan, K., Boland, A., Smith, G., Bagust, A., Duendar, Y., . . . Dickson, R. (2008). The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation: Abstract. HEALTH TECHNOLOGY ASSESSMENT, 12(12), 1-+. Retrieved from https://www.webofscience.com/
The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: A systematic review and economic evaluation
Hockenhull, J. C., Dwan, K., Boland, A., Smith, G., Bagust, A., Dündar, Y., . . . Dickson, R. (2008). The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: A systematic review and economic evaluation. Health Technology Assessment, 12(12). doi:10.3310/hta12120
2007
Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature.
Black, C., de Verteuil, R., Walker, S., Ayres, J., Boland, A., Bagust, A., & Waugh, N. (2007). Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature.. Thorax, 62(2), 131-138. doi:10.1136/thx.2006.064659
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod, C., Bagust, A., Boland, A., Dagenais, P., Dickson, R., Dundar, Y., . . . Walley, T. (2007). Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 11(28), 1-iv. doi:10.3310/hta11280
Drug-eluting stents: a systematic review and economic evaluation.
Hill, R. A., Boland, A., Dickson, R., Dündar, Y., Haycox, A., McLeod, C., . . . Bagust, A. (2007). Drug-eluting stents: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 11(46), iii-221. doi:10.3310/hta11460
2006
Principles and practices of health economics in evaluating oral health
Haycox, A., Boland, A., & Harris, R. (2006). Principles and practices of health economics in evaluating oral health. In C. Pine, & R. Harris (Eds.), Community oral health (pp. 1). Berlin: Quintessence.
The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: Systematic reviews
Black, C., Bagust, A., Boland, A., Walker, S., McLeod, C., De Verteuil, R., . . . Waugh, N. (2006). The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: Systematic reviews. Health Technology Assessment, 10(3). doi:10.3310/hta10030
The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews.
Black, C., Bagust, A., Boland, A., Walker, S., McLeod, C., De Verteuil, R., . . . Waugh, N. (2006). The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews.. Health technology assessment (Winchester, England), 10(3), iii-90. doi:10.3310/hta10030
2005
Patient and provider perspectives on home telecare: preliminary results from a randomized controlled trial.
Mair, F. S., Goldstein, P., May, C., Angus, R., Shiels, C., Hibbert, D., . . . Capewell, S. (2005). Patient and provider perspectives on home telecare: preliminary results from a randomized controlled trial.. Journal of telemedicine and telecare, 11 Suppl 1, 95-97. doi:10.1258/1357633054461976
'Patient and provider perspectives on home telecare: preliminary results from a randomized controlled trial'
Mair, F., Goldstein, P., May, C., Angus, R., Shiels, C., Hibbert, D., . . . Capewell, S. (2005). 'Patient and provider perspectives on home telecare: preliminary results from a randomized controlled trial'. Journal of Telemedicine and Telecare, 11(Suppl), 95-97.
Randomized controlled trial to evaluate the clinical- and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses
Boland, A., Haycox, A., Bagust, A., & Fitzsimmons, L. (2005). Randomized controlled trial to evaluate the clinical- and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. International Journal of Technology Assessment in Health Care, 21(1), 145-146. doi:10.1017/s0266462305230192
2004
Health professionals' responses to the introduction of a home telehealth service.
Hibbert, D., Mair, F. S., May, C. R., Boland, A., O'Connor, J., Capewell, S., & Angus, R. M. (2004). Health professionals' responses to the introduction of a home telehealth service.. Journal of telemedicine and telecare, 10(4), 226-230. doi:10.1258/1357633041424386
Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis.
Dündar, Y., Dodd, S., Strobl, J., Boland, A., Dickson, R., & Walley, T. (2004). Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis.. Human psychopharmacology, 19(5), 305-322. doi:10.1002/hup.594
Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation
Dundar, Y., Boland, A., Strobl, J., Dodd, S., Haycox, A., Bagust, A., . . . Walley, T. (2004). Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technology Assessment, 8(24), 1-140.
Newer hypnotic drugs for the short-term management of insomnia:: a systematic review and economic evaluation
Dündar, Y., Boland, A., Strobl, J., Dodd, S., Haycox, A., Bagust, A., . . . Walley, T. (2004). Newer hypnotic drugs for the short-term management of insomnia:: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 8(24), 1-+. Retrieved from https://www.webofscience.com/
Pharmacoeconomics
Walley, T., Haycox, A., & Boland, A. (2004). Pharmacoeconomics. Edinburgh: Churchill Livingstone.
Problems with implementation - the story of a home telecare trial
Mair, F., Hibbert, D., May, C., Angus, R., Finch, T., Boland, A., . . . Capewell, S. (2004). Problems with implementation - the story of a home telecare trial. In P. Whitten, & D. Cook (Eds.), Understanding Health Communications Technologies: A Case Study Approach (pp. unknown). San Fransisco: Jossey-Bass Inc.
2003
A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses
Boland, A., Haycox, A., Bagust, A., & Fitzsimmons, L. (2003). A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technology Assessment, 7(36).
A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses.
Boland, A., Haycox, A., Bagust, A., & Fitzsimmons, L. (2003). A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses.. Health technology assessment (Winchester, England), 7(36), iii-99. doi:10.3310/hta7360
Early thrombosis for the treatment of acute myocardial infarction: A systematic review and economic evaluation
Boland, A., Dundar, Y., Bagust, A., Haycox, A., Hill, R., Mujica Mota, R., . . . Dickson, R. (2003). Early thrombosis for the treatment of acute myocardial infarction: A systematic review and economic evaluation. Health Technology Assessment, 7(15).
A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses
Boland, A., Haycox, A., Bagust, A., & Fitzsimmons, L. (n.d.). A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technology Assessment, 7(36). doi:10.3310/hta7360
Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
Boland, A., Dundar, Y., Bagust, A., Haycox, A., Hill, R., Mujica Mota, R., . . . Dickson, R. (2003). Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 7(15), 1-136. doi:10.3310/hta7150
Lessons from the implementation of a home telecare service.
Hibbert, D., Mair, F. S., Angus, R. M., May, C., Boland, A., Haycox, A., . . . Capewell, S. (2003). Lessons from the implementation of a home telecare service.. Journal of telemedicine and telecare, 9 Suppl 1, S55-S56. doi:10.1258/135763303322196358
2002
'A randomized controlled trial of home telecare'
Mair, F., Boland, A., Angus, R., Haycox, A., Hibbert, D., Bonner, S., . . . Bundred, P. (2002). 'A randomized controlled trial of home telecare'. Journal of Telemedicine and Telecare, 8(Suppl), 58-60.
A randomized controlled trial of home telecare.
Mair, F., Boland, A., Angus, R., Haycox, A., Hibbert, D., Bonner, S., . . . Bundred, P. (2002). A randomized controlled trial of home telecare.. Journal of telemedicine and telecare, 8 Suppl 2, 58-60. doi:10.1177/1357633x020080s227